Zepbound Coupons and Savings (2026 Guide)
Every active Zepbound discount, compared side by side. Updated monthly.
The lowest Zepbound out-of-pocket price in 2026 is $25 per month via the Lilly Savings Card for patients with commercial insurance that covers Zepbound. Without insurance, LillyDirect Self Pay costs $299 to $449 per month for vials and the new Multi-Dose KwikPen. Income-qualified uninsured patients may qualify for free or reduced access through the Lilly Cares Patient Assistance Program. Medicare, Medicaid, Tricare, VA, and DOD plans are excluded from manufacturer coupons by law, though the November 2025 Most-Favored-Nation pricing framework is expected to change that.
Active Zepbound savings in 2026
Four programs, compared across eligibility, monthly cost, and how to claim. Prices verified this month.
Want Zepbound savings changes first?
We watch Lilly Savings Card terms, LillyDirect pricing, and coverage updates.
Which savings program fits you?
Start with your insurance status. Each branch ends at the lowest legal path available to you today.
Consider requesting a formulary exception first. Appeal process may unlock full coverage.
Savings Card is excluded for federal plans. Medicare coverage may begin as early as April 2026 per Trump administration announcement (Nov 2025). MFN pricing framework would cap Medicare copays at ~$50/mo. Medicaid coverage for obesity varies by state and changes frequently.
Telehealth Zepbound pricing by state
Aggregated from our directory of NPI-verified telehealth providers prescribing tirzepatide. Most patients find their cheapest path through a telehealth program rather than retail — these numbers show what clinics in each state actually publish.
Telehealth Zepbound pricing across 21 states
Aggregated from 767 telehealth clinics in our directory that prescribe zepbound. Median monthly program low is $499; cheapest published low is $499 in Pennsylvania.
| State | Clinics in directory | Lowest monthly | Median monthly low |
|---|---|---|---|
| Massachusetts | 30 | $199/mo | $499/mo |
| Pennsylvania | 30 | $499/mo | $499/mo |
| Texas | 150 | $499/mo | $499/mo |
| California | 95 | $499/mo | $499/mo |
| New York | 60 | $499/mo | $499/mo |
| Minnesota | 14 | $499/mo | $499/mo |
| Michigan | 23 | $499/mo | $499/mo |
| Florida | 89 | $499/mo | $499/mo |
| Washington | 20 | $499/mo | $499/mo |
| Arizona | 62 | $499/mo | $499/mo |
| Nevada | 19 | $499/mo | $499/mo |
| Indiana | 23 | $499/mo | $499/mo |
| New Mexico | 17 | $499/mo | $499/mo |
| Georgia | 19 | $499/mo | $499/mo |
| Illinois | 32 | $499/mo | $499/mo |
Cite this page
Published under CC BY 4.0 — free to reuse with attribution. Pick the format you need.
GLP1 Clinics. (2026). Telehealth Zepbound Pricing by State. https://www.glp1clinics.org/zepbound/coupon
According to GLP1 Clinics (2026)
<a href="https://www.glp1clinics.org/zepbound/coupon">Telehealth Zepbound Pricing by State</a> — GLP1 Clinics (2026)
[Telehealth Zepbound Pricing by State](https://www.glp1clinics.org/zepbound/coupon) — GLP1 Clinics (2026)
A note on compounded tirzepatide
FDA declared the tirzepatide injection shortage resolved on December 19, 2024. As of 2025-2026, pharmacies are no longer permitted to regularly compound tirzepatide injections. Narrow exceptions exist for documented patient-specific medical needs (e.g., allergy to inactive ingredients in commercial Zepbound).
Beware of counterfeit tirzepatide or providers claiming to offer compounded tirzepatide without documented patient-specific medical need. This is now a legal gray area with real safety risk.
Use LillyDirect Multi-Dose KwikPen ($299-$449) as the current primary cash-pay path. Compounded tirzepatide is no longer a reliable cost-saving option.
Frequently asked questions
Every question patients ask most often about Zepbound coupons and savings.
Not sure which option is right for you?
Take our 90-second quiz. We match you to the lowest-cost Zepbound path based on your insurance, location, and medical history.
Pricing verified against Lilly's official pricinginfo.lilly.com page, cross-referenced with Noom Med (March 2026), GoodRx, and Drugs.com. We do not accept payment for inclusion in any comparison. Medical content reviewed by Dr. Golsa Gholampour, MD, board-certified in obesity medicine. Quarterly re-verification scheduled.